Capabilities
GMP Manufacturing
State-of-the-Art Infrastructure for Viral Vector Production
ReiThera’s GMP facility is built to deliver end-to-end manufacturing for viral vector-based products, supporting both clinical development and commercial production. Strategically located and fully compliant with global regulatory standards, the site enables scalable and flexible production of ATMPs, including viral vaccines and gene therapies.
GMP Capabilities
Our manufacturing campus offers a fully integrated ecosystem for viral vector production
Facility Highlights
870 m² of cGMP production suites, including:
- 3 cleanroom cell culture suites
- Media/buffer preparation suites
- Three multi-purpose production rooms (Grade B/C)
- EC Grade B aseptic filling suite
In addition, an independent Small Scale production area (up to 2 L bulk) is available, equipped with:
- Cleanroom cell culture suite
- Dedicated production room
- EC Grade B aseptic filling suites
400 m² of dedicated QC laboratories for in-process control and batch release
GMP Infrastructure
3,470 m²
Total Area
870
m²
GMP production suites
400
m²
Quality control (QC) laboratories
700+
m²
GMP and research support services
1,500
m²
Newly validated expansion area
Bioreactor Technologies
Flexible Platforms for Diverse Viral Vectors
Our advanced bioreactor infrastructure is designed to support both suspension and adherent cell culture systems, enabling versatile and scalable viral vector manufacturing.
Bioreactor Capabilities:
- Disposable Stirred-Tank Bioreactors: Available in 200 L, 1,000 L, and 2,000 L scales for efficient large-scale production with reduced cross-contamination risk.
- Fixed-Bed Bioreactors: Offering up to 30 m² cultivation area, ideal for high-density adherent cell cultures.
- WAVE Bioreactors: Multiple systems, providing gentle mixing and optimal conditions for sensitive cell lines.
- Versatility Across Vector Types: Our platforms are fully compatible with the production of a broad range of viral vectors, including:
- Adenovirus (Ad)
- Adeno-Associated Virus (AAV)
- Modified Vaccinia Ankara (MVA)
- Herpes Simplex Virus (HSV)
With integrated scalability and precise process control, our systems support seamless transition from development to commercial-scale manufacturing
Aseptic Fill-Finish Capabilities
Our EC Class B fill-finish suite is designed to support both large- and small-batch production with maximum flexibility and sterility assurance.
Filling Technologies:
- Automated and Manual Filling Options
- oRABS Isolator System for fully aseptic operations
- Watson-Marlow Flexicon FCP50W Automated Filler for precise, reproducible dispensing
- Manual Filling Stations tailored for small-scale and early-phase batches
The platform supports up to 3,500 vials per batch, providing the flexibility required for personalized therapies and niche indications.